Direct antimicrobial susceptibility testing of bloodstream infection on SlipChip

Yi, Qiaolian; Cai, Dongyang; Xiao, Meng; Nie, Mengyue; Cui, Qinna; Cheng, Jingwei; Li, Caiming; Feng, Jie; Urban, G.; Xu, Yingchun; Lan, Ying; Du, Wei

doi:10.1016/j.bios.2019.04.003

Cited by 38 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concept was tested for AST of positive blood cultures. The results were consistent with standard microdilution tests or the BD Phoenix System when several broad-spectrum antibiotics and clinical E. coli samples as well as the S. aureus ATCC 6538 strain were tested (Yi et al, 2019 ). The Talis Biomedical Corporation (CA, USA) is currently commercializing dAST/SlipChip technology to a product which combines a single-use cartridge integrating fluid partitioning for parallel treatment with different antimicrobials, reagent additions, target lysis, extraction and amplification.…”

Section: Poct-compatible Devices For Id and Astsupporting

confidence: 77%

Modern Tools for Rapid Diagnostics of Antimicrobial Resistance

Vasala

Hytönen

Laitinen

2020

Front. Cell. Infect. Microbiol.

230

146

View full text Add to dashboard Cite

Fast, robust, and affordable antimicrobial susceptibility testing (AST) is required, as roughly 50% of antibiotic treatments are started with wrong antibiotics and without a proper diagnosis of the pathogen. Validated growth-based AST according to EUCAST or CLSI (European Committee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute) recommendations is currently suggested to guide the antimicrobial therapy. Any new AST should be validated against these standard methods. Many rapid diagnostic techniques can already provide pathogen identification. Some of them can additionally detect the presence of resistance genes or resistance proteins, but usually isolated pure cultures are needed for AST. We discuss the value of the technologies applying nucleic acid amplification, whole genome sequencing, and hybridization as well as immunodiagnostic and mass spectrometry-based methods and biosensor-based AST. Additionally, we evaluate the potential of integrated systems applying microfluidics to integrate cultivation, lysis, purification, and signal reading steps. We discuss technologies and commercial products with potential for Point-of-Care Testing (POCT) and their capability to analyze polymicrobial samples without pre-purification steps. The purpose of this critical review is to present the needs and drivers for AST development, to show the benefits and limitations of AST methods, to introduce promising new POCT-compatible technologies, and to discuss AST technologies that are likely to thrive in the future.

show abstract

Section: Poct-compatible Devices For Id and Astsupporting

confidence: 77%

Modern Tools for Rapid Diagnostics of Antimicrobial Resistance

Vasala

Hytönen

Laitinen

2020

Front. Cell. Infect. Microbiol.

230

146

View full text Add to dashboard Cite

show abstract

“…Such devices typically contain two parallel plates which can be moved to fill and close micro to picolitre-volume wells. 14,29 While the throughput is limited, these designs have other advantages, e.g. the chambers can be supplied with compounds, medium or antibiotics at a later time in the experiment, hence providing the possibility of tracking the bacterial growth in response to changes of cultivation conditions over time.…”

Section: Introductionmentioning

confidence: 99%

Real-time respiration changes as a viability indicator for rapid antibiotic susceptibility testing in a microfluidic chamber array

Jusková

Schmitt

Kling

et al. 2021

Preprint

View full text Add to dashboard Cite

Rapid identification of a pathogen and the measurement of its antibiotic susceptibility are key elements in the diagnostic process of bacterial infections. Microfluidic technologies offer great control over handling and manipulation of low sample volumes with the possibility to study microbial cultures on the single-cell level. Downscaling the dimensions of cultivation systems directly results in a lower number of bacteria required for antibiotic susceptibility testing (AST) and thus in a reduction of the time to result. The developed platform presented in this work allows the reading of pathogen resistance profiles within 2-3 hours based on the changes of the dissolved oxygen levels during bacterial cultivation. The platform contains hundreds of individual growth chambers prefilled with a hydrogel containing oxygen-sensing nanoprobes and different concentrations of antibiotic compounds. The performance of the microfluidic platform is tested using quality control Escherichia coli strains (ATCC 25922 and ATCC 35218) in response to different clinically relevant antibiotics. The achieved results are in agreement with values given in clinical reference guides and independent measurements using a clinical AST protocol. Finally, the platform is successfully used for AST of an E. coli clinical isolate obtained from a patient blood culture.

show abstract

“…Microfluidic technology capable of manipulating small volumes of fluid and integrating a variety of reactions holds great promise for viral nucleic acid testing [18][19][20][21][22][23][24][25][26][27][28][29]. For example, microfluidics combined with a commercially available coffee mug or portable heating device allowed for sensitive and rapid detection of Zika virus by integrating RNA extraction, enrichment, and amplification in a microfluidic device [30][31][32].…”

Section: Introductionmentioning

confidence: 99%

A fully automated centrifugal microfluidic system for sample-to-answer viral nucleic acid testing

et al. 2020

View full text Add to dashboard Cite

The outbreak of virus-induced infectious diseases poses a global public-health challenge. Nucleic acid amplification testing (NAAT) enables early detection of pandemic viruses and plays a vital role in preventing onward transmission. However, the requirement of skilled operators, expensive instrumentation, and biosafety laboratories has hindered the use of NAAT for screening and diagnosis of suspected patients. Here we report development of a fully automated centrifugal microfluidic system with sample-in-answer-out capability for sensitive, specific, and rapid viral nucleic acid testing. The release of nucleic acids and the subsequent reverse transcription loop-mediated isothermal amplification (RT-LAMP) were integrated into the reaction units of a microfluidic disc. The whole processing steps such as injection of reagents, fluid actuation by rotation, heating and temperature control, and detection of fluorescence signals were carried out automatically by a customized instrument. We validate the centrifugal microfluidic system using oropharyngeal swab samples spiked with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) armored RNA particles. The estimated limit of detection for armored RNA particles is 2 copies per reaction, the throughput is 21 reactions per disc, and the assay sample-to-answer time is approximately 70 min. This enclosed and automated microfluidic system efficiently avoids viral contamination of aerosol, and can be readily adapted for virus detection outside the diagnostic laboratory. Electronic Supplementary Material Supplementary material is available for this article at 10.1007/s11426-020-9800-6 and is accessible for authorized users.

show abstract

Direct antimicrobial susceptibility testing of bloodstream infection on SlipChip

Cited by 38 publications

References 39 publications

Modern Tools for Rapid Diagnostics of Antimicrobial Resistance

Modern Tools for Rapid Diagnostics of Antimicrobial Resistance

Real-time respiration changes as a viability indicator for rapid antibiotic susceptibility testing in a microfluidic chamber array

A fully automated centrifugal microfluidic system for sample-to-answer viral nucleic acid testing

Contact Info

Product

Resources

About